Breaking Boundaries in Malaria Research: Design of a Genetic Tool for High-Throughput Gametocidal Drug Screening
DOI:
https://doi.org/10.21814/jus.5702Keywords:
Malaria; Drug Screening; Gametocytes; Genome-editing strategies; Plasmodium falciparum.Abstract
Malaria, a devastating illness remains a global health concern with an estimated 249 million malaria cases in 85 malaria-endemic countries around the world. Malaria elimination, challenged by drug resistance, requires strategic interventions that could be the implementation of antimalarials with selective actions on the different phases of the parasite life cycle. Of particular relevance is gametocytocidal drugs that could be used to prevent transmission of malaria infection to the mosquito.
Finding drugs with gametocidal effect thus are limited by the technical challenges of large-scale production and quantification of parasite transmission stage, gametocytes. To surmount these obstacles, our study endeavors to design a genetic engineering strategy (a vector construct) to further deliver nucleic acid information through transfections-based systems in the form of a plasmid into Plasmodium falciparum. This approach will enable us to engineer a transgenic parasite line for multi-stage drug screening, targeting the symptomatic intra-erythrocyte parasite stage and gametocytes.
Genetic engineering tools such as selected linked integration system and attB-attP site-specific recombination will be used in our vector construct aiming the genetic integration process into the P. falciparum genome. These systems will accommodate strategies for easy and accurate stage-specific quantification such as RFP-luciferase fusion cloned downstream stage-specific promoters leading to reporter products with optical outputs and for efficient production of gametocytes at large scale using a riboswitch-based inducible gene expression system. Such technology is of major need and will pave the way for scaling up the capacity for high-throughput drug screening, leading to improved strategies to find drugs capable of blocking malaria transmission.
References
"World malaria report 2022". Accessed: Sep. 14, 2023. [Online]. Available: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022
C.-C. for D. C. and Prevention, "CDC - Malaria - About Malaria - Biology". Accessed: Sep. 14, 2023. [Online]. Available: https://www.cdc.gov/malaria/about/biology/index.html
M. Crockett and K. C. Kain, "Tafenoquine: a promising new antimalarial agent", Expert Opin Investig Drugs, vol. 16, no. 5, pp. 705–715, May 2007, doi: 10.1517/13543784.16.5.705. DOI: https://doi.org/10.1517/13543784.16.5.705
A. Dicko et al., "Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial", The Lancet Infectious Diseases, vol. 18, no. 6, pp. 627–639, Jun. 2018, doi: 10.1016/S1473-3099(18)30044-6. DOI: https://doi.org/10.1016/S1473-3099(18)30044-6
"G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map | PLOS Medicine". Accessed: Mar. 10, 2024. [Online]. Available: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001339
M. J. Delves et al., "Routine in vitro culture of P. falciparum gametocytes to evaluate novel transmission-blocking interventions", Nat Protoc, vol. 11, no. 9, pp. 1668–1680, Sep. 2016, doi: 10.1038/nprot.2016.096. DOI: https://doi.org/10.1038/nprot.2016.096
Q. L. Fivelman et al., "Improved synchronous production of Plasmodium falciparum gametocytes in vitro", Mol Biochem Parasitol, vol. 154, no. 1, pp. 119–123, Jul. 2007, doi: 10.1016/j.molbiopara.2007.04.008. DOI: https://doi.org/10.1016/j.molbiopara.2007.04.008
J. W. Field and P. G. Shute, "The Microscopic Diagnosis of Human Malaria. II. A Morphological Study of the Erythroeytic Parasites.", 1956. Accessed: Sep. 16, 2023. [Online]. Available: https://www.semanticscholar.org/paper/The-Microscopic-Diagnosis-of-Human-Malaria.-II.-A-Field-Shute/4d2310230eedbb7870e29cdd92ab62c406e1e536
G. Siciliano and P. Alano, "Enlightening the malaria parasite life cycle: bioluminescent Plasmodium in fundamental and applied research", Front. Microbiol., vol. 6, May 2015, doi: 10.3389/fmicb.2015.00391. DOI: https://doi.org/10.3389/fmicb.2015.00391
R. Carter and L. H. Miller, "Evidence for environmental modulation of gametocytogenesis in Plasmodium falciparum in continuous culture", Bull World Health Organ, vol. 57 Suppl 1, pp. 37–52, 1979.
C. Ngwa, T. Ferreira de Araujo Rosa, and G. Pradel, "The Biology of Malaria Gametocytes", 2016. doi: 10.5772/65464. DOI: https://doi.org/10.5772/65464
M. C. Bruce, R. N. Carter, K. Nakamura, M. Aikawa, and R. Carter, "Cellular location and temporal expression of the Plasmodium falciparum sexual stage antigen Pfs16", Mol Biochem Parasitol, vol. 65, no. 1, pp. 11–22, May 1994, doi: 10.1016/0166-6851(94)90111-2. DOI: https://doi.org/10.1016/0166-6851(94)90111-2
J. Ramelow, Y. Keleta, G. Niu, X. Wang, and J. Li, "Plasmodium parasitophorous vacuole membrane protein Pfs16 promotes malaria transmission by silencing mosquito immunity", J Biol Chem, vol. 299, no. 6, p. 104824, May 2023, doi: 10.1016/j.jbc.2023.104824. DOI: https://doi.org/10.1016/j.jbc.2023.104824
L. Sun, B. M. Lutz, e Y.-X. Tao, “The CRISPR/Cas9 system for gene editing and its potential application in pain research”, Transl. Perioper. Pain Med., vol. 1, n.o 3, pp. 22–33, 2016. 12. DOI: https://doi.org/10.31480/2330-4871/040
“Selection linked integration (SLI) for endogenous gene tagging and knock sideways in Plasmodium falciparum parasites”. Acessed: 3rd February 2024. [Online]. Available on: https://www.researchsquare.com.
P. Balabaskaran-Nina e S. A. Desai, “Diverse target gene modifications in Plasmodium falciparum using Bxb1 integrase and an intronic attB”, Parasit. Vectors, vol. 11, p. 548, out. 2018, doi: 10.1186/s13071-018-3129-5. DOI: https://doi.org/10.1186/s13071-018-3129-5
L. J. Nkrumah et al., “Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase”, Nat. Methods, vol. 3, n.o 8, pp. 615–621, ago. 2006, doi: 10.1038/nmeth904. DOI: https://doi.org/10.1038/nmeth904
J. Hoshizaki, H. Jagoe, e M. C. S. Lee, “Efficient generation of mNeonGreen Plasmodium falciparum reporter lines enable quantitative fitness analysis”, Front. Cell. Infect. Microbiol., vol. 12, p. 981432, set. 2022, doi: 10.3389/fcimb.2022.981432. DOI: https://doi.org/10.3389/fcimb.2022.981432
H. P. Portugaliza, O. Llorà-Batlle, A. Rosanas-Urgell, e A. Cortés, “Reporter lines based on the gexp02 promoter enable early quantification of sexual conversion rates in the malaria parasite Plasmodium falciparum”, Sci. Rep., vol. 9, n.o 1, Art. n.o 1, out. 2019, doi: 10.1038/s41598-019-50768-y. DOI: https://doi.org/10.1038/s41598-019-50768-y
Y. Miyazaki et al., “A versatile Plasmodium falciparum reporter line expressing NanoLuc enables highly sensitive multi-stage drug assays”, Commun. Biol., vol. 6, n.o 1, pp. 1–15, jul. 2023, doi: 10.1038/s42003-023-05078-5. DOI: https://doi.org/10.1038/s42003-023-05078-5
C. Marin-Mogollon et al., “A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages”, Front. Cell. Infect. Microbiol., vol. 9, 2019, Acessed: 26th September 2022. [Online]. Available on: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00096 DOI: https://doi.org/10.3389/fcimb.2019.00096
F. Hawking, M. E. Wilson, e K. Gammage, “Evidence for cyclic development and short-lived maturity in the gametocytes of Plasmodium falciparum.”, Trans. R. Soc. Trop. Med. Hyg., vol. 65, n.o 5, pp. 549–59, 1971. DOI: https://doi.org/10.1016/0035-9203(71)90036-8
M. E. Matlashov et al., “A set of monomeric near-infrared fluorescent proteins for multicolor imaging across scales”, Nat. Commun., vol. 11, n.o 1, p. 239, dez. 2020, doi: 10.1038/s41467-019-13897-6. DOI: https://doi.org/10.1038/s41467-019-13897-6
C. A. Combs, “Fluorescence Microscopy: A Concise Guide to Current Imaging Methods”, Curr. Protoc. Neurosci. Editor. Board Jacqueline N Crawley Al, vol. 0 2, p. Unit2.1, jan. 2010, doi: 10.1002/0471142301.ns0201s50. DOI: https://doi.org/10.1002/0471142301.ns0201s50
K. Kulkeaw, “Progress and challenges in the use of fluorescence‐based flow cytometric assays for anti‐malarial drug susceptibility tests”, Malar. J., vol. 20, n.o 1, p. 57, jan. 2021, doi: 10.1186/s12936-021-03591-8. DOI: https://doi.org/10.1186/s12936-021-03591-8
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Beatriz Velosa da Fonseca
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Uminho Science (JUS) magazine, in order to protect the interests of the authors of the articles and also their own, follows the terms and conditions of "Creative Commons Atribution 4.0 International Public License" whose credit belongs to “Creative Commons” (creativecommons.org).
By agreeing to the terms of this license you are granting us your permission to use your item under the terms and conditions specified in this license.
"By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.
Section 1 – Definitions.
Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.
Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.
Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.
Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.
Licensor means the individual(s) or entity(ies) granting rights under this Public License.
Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.
Section 2 – Scope.
License grant.
Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
- Reproduce and Share the Licensed Material, in whole or in part; and
- Produce, reproduce, and Share Adapted Material.
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
Term. The term of this Public License is specified in Section 6(a).
Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
Downstream recipients.
Offer from the Licensor – Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
Other rights.
Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
Patent and trademark rights are not licensed under this Public License.
To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties.
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
Attribution.
If You Share the Licensed Material (including in modified form), You must retain the following if it is supplied by the Licensor with the Licensed Material:
- Identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
- A copyright notice;
- A notice that refers to this Public License;
- A notice that refers to the disclaimer of warranties;
- A URI or hyperlink to the Licensed Material to the extent reasonably practicable;
- Indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
- Indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:
- For the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database;
- If You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material;
- You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
Unless otherwise separately undertaken by the Licensor, to the extent possible, the Licensor offers the Licensed Material as-is and as-available, and makes no representations or warranties of any kind concerning the Licensed Material, whether express, implied, statutory, or other. This includes, without limitation, warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of latent or other defects, accuracy, or the presence or absence of errors, whether or not known or discoverable. Where disclaimers of warranties are not allowed in full or in part, this disclaimer may not apply to You.
To the extent possible, in no event will the Licensor be liable to You on any legal theory (including, without limitation, negligence) or otherwise for any direct, special, indirect, incidental, consequential, punitive, exemplary, or other losses, costs, expenses, or damages arising out of this Public License or use of the Licensed Material, even if the Licensor has been advised of the possibility of such losses, costs, expenses, or damages. Where a limitation of liability is not allowed in full or in part, this limitation may not apply to You.
The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.
Section 6 – Term and Termination.
This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
- Automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation;
- Or, upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 – Other Terms and Conditions.
The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.
Section 8 – Interpretation.
For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority."
